{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017003", "CSN": null, "TRF": "ORD_1220222_01", "MRN": "2890553", "PhysicianId": "48026", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "930238", "clinicalId": "931622", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1220222_01", "SampleName": "US1179002.01", "Version": "0", "Sample": {"FM_Id": "ORD_1220222_01", "SampleId": "US1179002.01", "BlockId": "K12116401(From\u5f70\u57fa)", "TRFNumber": "ORD_1220222_01", "TestType": "FoundationOne Heme", "SpecFormat": "FFPE", "ReceivedDate": "2021_10_25", "processSites": {"processSite": [{"address": "7010 Kit Creek Road, Morrisville, NC 27560", "cliaNumber": "34D2044309", "locationID": "2", "locationName": "RTP", "processID": "2", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-89472", "MRN": "2890553", "FullName": "\u738b\u516c\u5a01", "FirstName": "Kung_Wei", "LastName": "Wang", "SubmittedDiagnosis": "Diffuse large B-cell lymphoma, Testis", "Gender": "Male", "DOB": "1941_07_08", "OrderingMD": "\u694a\u6155\u83ef", "OrderingMDId": "48026", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Testis", "CollDate": "2021_09_28", "ReceivedDate": "2021-11-15 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Large B-Cell Lymphoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "40", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "BCL11B", "isVUS": "true", "variantName": "A586V"}, {"geneName": "BIRC3", "isVUS": "true", "variantName": "F176V"}, {"geneName": "DUSP2", "isVUS": "true", "variantName": "L67F"}, {"geneName": "ERBB3", "isVUS": "true", "variantName": "R1309H"}, {"geneName": "ETS1", "isVUS": "true", "variantName": "T10I"}, {"geneName": "FANCC", "isVUS": "true", "variantName": "T367K"}, {"geneName": "FANCE", "isVUS": "true", "variantName": "G175D"}, {"geneName": "FGF19", "isVUS": "true", "variantName": "R61H"}, {"geneName": "GPR124", "isVUS": "true", "variantName": "C1196Y,D1313V"}, {"geneName": "IDH1", "isVUS": "true", "variantName": "R20Q"}, {"geneName": "IKBKE", "isVUS": "true", "variantName": "A346V"}, {"geneName": "KDM4C", "isVUS": "true", "variantName": "G799V"}, {"geneName": "MDM4", "isVUS": "true", "variantName": "N281S"}, {"geneName": "PIM1", "isVUS": "true", "variantName": "A10V,E70*,G102D,G137V,G28D,L177F,L184F,P81S,R57G,S312N,T204fs*31"}, {"geneName": "PRKDC", "isVUS": "true", "variantName": "T1375S"}, {"geneName": "RAD51", "isVUS": "true", "variantName": "R97H"}, {"geneName": "TBL1XR1", "isVUS": "true", "variantName": "W316S"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "22", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "22"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). Associations of TMB levels with sensitivity to immune checkpoint inhibitors have not been extensively characterized in hematologic malignancies and the effects of TMB on therapeutic outcomes in this context are unclear. Diffuse large B_cell lymphoma (DLBCL) harbors a median TMB of 10 mutations per megabase (muts/Mb), and 18.4% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). Increased mutation burden has been identified in DLBCL at relapse compared to at diagnosis (Wise et al., 2015; ASH Abstract 110). In one study, TMB was significantly higher in DLBCL (44% with >10 muts/Mb) as compared to low_grade non_Hodgkin lymphoma (LGNHL; 0% with >10 muts/Mb; p<0.0001); IHC testing in a separate cohort showed higher PD_L1 expression in DLBCL (8/10 PD_L1 positive) as compared to LGNHL (2/10 PD_L1 positive) (p=0.01), thereby suggesting possible benefit of checkpoint inhibitor therapy in DLBCL (Karim et al., 2017; AACR Abstract 3724). Aberrant somatic hypermutation occurs frequently in the primary central nervous system lymphoma (PCNSL) subtype and often targets the IGH, IGK, IGL, MYC, PAX5, BCL2, RhoH, and PIM1 genes (Montesinos_Rongen et al., 2004; 14592832, Montesinos_Rongen et al., 2014; 25383641, Vater et al., 2015; 25189415, Thompsett et al., 1999; 10477699, Deckert et al., 2014; 24240734). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). As it is unclear whether TMB is associated with efficacy of immune checkpoint inhibitors in hematological malignancies, it is unknown whether this approach would be relevant here.", "Include": "true", "ClinicalTrialNote": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03674567", "Include": "true"}, {"nctId": "NCT03207867", "Include": "true"}, {"nctId": "NCT04261439", "Include": "true"}, {"nctId": "NCT04476459", "Include": "true"}, {"nctId": "NCT02500407", "Include": "true"}, {"nctId": "NCT03005782", "Include": "true"}, {"nctId": "NCT04070040", "Include": "true"}, {"nctId": "NCT01703949", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03244176", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "B2M", "Include": "true", "Alterations": {"Alteration": {"Name": "M1?, T24fs*52", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "M1?"}, {"isEquivocal": "false", "name": "T24fs*52"}]}, "Interpretation": "B2M encodes beta_2_microglobulin, a component of the MHC complex that presents antigen peptides to the immune system and binds the inhibitory receptor LILRB1 on macrophages. Alterations in B2M that lead to loss, truncation, destabilization, or aberrant expression of beta_2_microglobulin can promote tumor evasion of immunosurveillance through loss of MHC presentation (Challa_Malladi et al., 2011; 22137796, Bernal et al., 2012; 22833104, Reichel et al., 2015; 25488972, Rosa et al., 1983; 11894933). In hematologic malignancies, B2M alterations have been primarily reported in both germinal center B_cell like and activated B_cell diffuse large B_cell lymphoma (DLBCL), with mutations and deletions present in 13% and 25% of DLBCL cases, respectively, and biallelic loss due to mutation or deletion in 13% of cases (Challa_Malladi et al., 2011; 22137796, de Miranda et al., 2014; 25171927). Inactivating B2M mutations have also been reported in classical Hodgkin lymphoma (Riechel et al., 2015; 25488972). In one study of classical Hodgkin lymphoma, B2M mutations were closely associated with loss of beta_2_microglobulin protein expression, and reduced beta_2_microglobulin expression was significantly associated with improved prognosis and the nodular sclerosis histologic subtype rather than the mixed cellularity subtype (Riechel et al., 2015; 25488972). High serum levels of beta_2_microglobulin have been correlated with poor prognosis in hematologic malignancies such as Hodgkin and non_Hodgkin lymphoma (Yoo et al., 2014; 25325033, Hagberg et al., 1983; 6189572, Nakajima et al., 2014; 25142947, Albitar et al., 2007; 16545870, Johnson et al., 1993; 8471438), including follicular lymphoma (Federico et al., 2007; 18024396, Federico et al., 2009; 19652063, Proch\u00e1zka et al., 2014; 24180329), DLBCL (Seo et al., 2014; ASH Abstract 2982, Miyashita et al., 2015; 26350140), mantle cell lymphoma (Yoo et al., 2016; 25689467), and NK/T_cell lymphoma (Li et al., 2012; 22373550, Yoo et al., 2014; 24441948), as well as in multiple myeloma (Durie et al., 1990; 2405920, Rossi et al., 2010; 20198709, Tricot et al., 1997; 9215838, Stella_Holowiecka et al., 2007; 18022010, Alexanian et al., 1985; 3907332, Barlogie et al., 1998; 9645572, Tricot et al., 2002; 11841419, Prince et al., 2007; 17325847), myelodysplastic syndrome (Gatto et al., 2003; 12738677, Neumann et al., 2009; 18639338), acute myeloid leukemia (Melillo et al., 1992; 1405762), acute lymphocytic leukemia (Kantarjian et al., 1992; 1466355), chronic lymphocytic leukemia (Shvidel et al., 2014; 24547751), and Waldenstrom macroglobulinemia (Dhodapkar et al., 2009; 18931340). Clinical and preclinical studies in melanoma, lung cancer, and colorectal cancer (CRC) suggest that B2M mutation or loss may be a mechanism of tumor escape from immune recognition (Wang et al., 1993; 8432869, D Urso et al., 1991; 1898655, Restifo et al., 1996; 8537970, Sucker et al., 2014; 25294904, Zhao et al., 2016; 27261508, del Campo et al., 2014; 23784959) and a resistance mechanism to immune checkpoint inhibitor (ICI) therapies (Zaretsky et al., 2016; 27433843, Gettinger et al., 2017; 29025772, Le et al., 2017; 28596308; Sade_Feldman et al., 2017; 29070816, Gurjao et al., 2019; 31217164). However, the effect of B2M inactivation on ICI outcomes may be context dependent, as a pan_cancer meta_analysis did not find B2M mutations to be a significantly associated with clinical response to ICIs overall but observed notable effects on ICI outcomes in select tumor type cohorts (melanoma, head and neck squamous cell carcinoma, and non_small cell lung cancer) (Litchfield et al. 2021; 33508232). Furthermore, patients with B2M_mutated CRC experienced clinical benefit (clinical benefit rate of 85% [11/13] overall and 91% [10/11] in MSI_H CRC) on ICI therapies (Middha et al., 2019; 31008436).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CARD11", "Include": "true", "Alterations": {"Alteration": {"Name": "K215N", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "K215N"}}, "Interpretation": "CARD11 (also known as CARMA1) is a scaffold protein critical for B_ and T_cell receptor_mediated NF_kappaB (NF_kB) activation (Weil et al., 2004; 15134788, Paul et al., 2013; 23474202, Juilland et al., 2016; 27135977). Activating CARD11 mutations, often occurring within the CARD (aa 18_110) or coiled_coil (aa 130_499) domains, can facilitate constitutive NF_kB signaling, proliferation, and cell survival in lymphomas (Juilland et al., 2016; 27135977, Bognar et al., 2016; 26776161, Chan et al., 2013; 23149938, Brohl et al., 2014; 25352053, Jeelall et al., 2012; 23027925, Lenz et al., 2008; 18323416, Lamason et al., 2010; 20799731, Dong et al., 2011; 21266526, Compagno et al., 2009; 19412164, da Silva Almeida et al., 2015; 26551667, Vallois et al., 2016; 27369867). Preclinical evidence suggests that activating CARD11 mutations may reduce sensitivity to ibrutinib, lenalidomide, and sotrastaurin in lymphoma (Wu et al., 2016; 27224912, Nagel et al., 2015; 26540570, Naylor et al., 2011; 21324920). Some germline CARD11 mutations have been found to underlie B_cell expansion with NF_kB and T_cell anergy (BENTA), a disorder characterized by congenital B_cell lymphocytosis (Snow et al., 2012; 23129749, Brohl et al., 2015; 25352053, Juilland et al., 2016; 27135977). CARD11 alterations have been most frequently reported in B_cell lymphomas, including diffuse large B_cell lymphoma (DLBCL; 11_23%)(Bu et al., 2012; 22397314, Lenz et al., 2008; 18323416, Morin et al., 2013; 23699601), follicular lymphoma (21_25%)(Morin et al., 2011; 21796119), primary central nervous system lymphoma (16_30%)(Montesinos_Rongen et al., 2010; 20544211, Braggio et al., 2015; 25991819), splenic marginal zone lymphoma (7_9%)(Rossi et al., 2012; 22891273; Yan et al., 2012; 22102703), and mantle cell lymphoma (6%)(Wu et al., 2016; 27224912). CARD11 mutations have also been detected in T_cell lymphomas, specifically in angioimmunoblastic T_cell lymphomas (AITLs), peripheral T_cell lymphomas (PTCLs), and cases of Sezary syndrome (Vallois et al., 2016; 27369867, Wang et al., 2015; 26551670, da Silva Almeida et al., 2015; 26551667). Copy number gains and consequent CARD11 overexpression have been reported in 71% (12/17) of patients with aggressive AITL and in 41% (30/73) of patients with PTCL (Oshiro et al., 2006; 16484591, Fujiwara et al., 2008; 18633432). Increased CARD11 expression has also been observed in T_ALL (Ma et al., 2014; 25384343). CARD11 amplification in DLBCL and increased CARD11 protein expression in AITL or PTCL is associated with reduced overall survival (Bu et al., 2012; 22397314, Fujiwara et al., 2008; 18633432). Although CARD11 mutations have been detected in a variety of solid tumors (cBio_Krauthammer et al., 2012; 22842228, cBio_Hodis et al., 2012; 22817889, cBio_Witkiewicz et al., 2015; 25855536, Cancer Genome Atlas Research Network., 2014; 25079317, Cancer Genome Atlas Research Network., 2014; 25079552, Cancer Genome Atlas Research Network., 2014; 24476821), the prognostic implications of CARD11 alterations in non_hematological malignancies are unclear. Although there are no therapies targeting CARD11 alterations, a number of drugs that block NF_kB activation are under investigation (Thome et al., 2010; 20685844, Lim et al., 2012; 22435566, Milhollen et al., 2010; 20525923). Preclinical evidence from models of mantle cell lymphoma suggests that tumors with CARD11 mutations may exhibit reduced sensitivity to inhibitors of BCR/NF_kB signaling including ibrutinib and lenalidomide (Wu et al., 2016; 27224912, Nagel et al., 2015; 26540570). CARD11 mutations have also been correlated with reduced sensitivity to sotrastaurin (protein kinase C inhibitor) in preclinical models of DLBCL (Naylor et al., 2011; 21324920).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": [{"Name": "CDKN2B loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2B loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Deletion of the CDKN2A/B locus on chromosome 9p21 is relatively common in B_cell lymphoma, reported primarily in diffuse large B_cell lymphoma (DLBCL), in which it is seen in 32% of cases (Guney et al., 2012; 22619049), as well as in 13% of follicular lymphoma (FL) cases (Schwaenen et al., 2009; 18828156). CDKN2A inactivation has been reported in 21_36% of DLBCL cases (Jardin et al., 2010; 20435884, Guney et al., 2012; 22619049, Schmitz et al., 2012; 22885699, Pasqualucci et al., 2011; 21804550, Lenz et al., 2008; 18765795) and in 6_13% of FL cases, particularly in higher grade FL cases, and in 33% of FL cases transformed to DLBCL (Schwaenen et al., 2009; 18828156, Pinyol et al., 1998; 9531609, M\u00f8ller et al., 1999; 10086736, Lossos and Levy, 2003; 12959350, Elenitoba_Johnson et al., 1998; 9616165, Fitzgibbon et al., 2007; 17495976). CDKN2A/B loss via deletion or methylation has been associated with reduced mRNA expression and higher grade malignancy in B_cell and T_cell lymphomas (Baur et al., 1999; 10477703, Guney et al., 2012; 22619049) and is also correlated with poor prognosis in FL patients (HR=3.6, p=0.0352), although many of these patients were treated prior to rituximab becoming a widely used therapy (Schwaenen et al., 2009; 18828156). Deletion of CDKN2A/B is not mutually exclusive with TP53 or MDM2 alterations and may be associated with the transformation of FL to DLBCL (Schwaenen et al., 2009; 18828156, Fitzgibbon et al., 2007; 17495976, M\u00f8ller et al., 1999; 10086736, Lossos and Levy, 2003; 12959350, Elenitoba_Johnson et al., 1998; 9616165). An array comparative genome hybridization (aCGH) study identified loss of the CDKN2A/B locus as a candidate marker for chemoresistance in B_cell lymphoma (Kreisel et al., 2011; 21504712). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "CDKN2A loss", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "CDKN2A loss"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Deletion of the CDKN2A/B locus on chromosome 9p21 is relatively common in B_cell lymphoma, reported primarily in diffuse large B_cell lymphoma (DLBCL), in which it is seen in 32% of cases (Guney et al., 2012; 22619049), as well as in 13% of follicular lymphoma (FL) cases (Schwaenen et al., 2009; 18828156). CDKN2A inactivation has been reported in 21_36% of DLBCL cases (Jardin et al., 2010; 20435884, Guney et al., 2012; 22619049, Schmitz et al., 2012; 22885699, Pasqualucci et al., 2011; 21804550, Lenz et al., 2008; 18765795) and in 6_13% of FL cases, particularly in higher grade FL cases, and in 33% of FL cases transformed to DLBCL (Schwaenen et al., 2009; 18828156, Pinyol et al., 1998; 9531609, M\u00f8ller et al., 1999; 10086736, Lossos and Levy, 2003; 12959350, Elenitoba_Johnson et al., 1998; 9616165, Fitzgibbon et al., 2007; 17495976). CDKN2A/B loss via deletion or methylation has been associated with reduced mRNA expression and higher grade malignancy in B_cell and T_cell lymphomas (Baur et al., 1999; 10477703, Guney et al., 2012; 22619049) and is also correlated with poor prognosis in FL patients (HR=3.6, p=0.0352), although many of these patients were treated prior to rituximab becoming a widely used therapy (Schwaenen et al., 2009; 18828156). Deletion of CDKN2A/B is not mutually exclusive with TP53 or MDM2 alterations and may be associated with the transformation of FL to DLBCL (Schwaenen et al., 2009; 18828156, Fitzgibbon et al., 2007; 17495976, M\u00f8ller et al., 1999; 10086736, Lossos and Levy, 2003; 12959350, Elenitoba_Johnson et al., 1998; 9616165). An array comparative genome hybridization (aCGH) study identified loss of the CDKN2A/B locus as a candidate marker for chemoresistance in B_cell lymphoma (Kreisel et al., 2011; 21504712). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "MLL2", "Include": "true", "Alterations": {"Alteration": {"Name": "P4961fs*1", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "P4961fs*1"}}, "Interpretation": "MLL2 encodes an H3K4_specific histone methyltransferase that is involved in the transcriptional response to progesterone signaling (Vicent et al., 2011; 21447625). Germline de novo mutations of MLL2 are responsible for the majority of cases of Kabuki syndrome, a complex and phenotypically distinctive developmental disorder (Hannibal et al., 2011; 21671394). A significant number of inactivating MLL2 alterations have been observed in multiple tumor types, suggesting a tumor suppressor role (Fagan et al.,2019; 31128216). Somatic alterations of MLL2 are frequently observed in lymphoma, including in the majority of follicular lymphomas, where the observed pattern of genomic alterations suggests a tumor suppressor function (Morin et al., 2011; 21796119). High protein expression of MLL2 has been correlated with higher clinical stage, and poorer overall survival in patients >60 years of age with gastrointestinal diffuse large B cell lymphoma (PGI_DLBCL) (Ye et al., 2015; 26722499). There are no targeted therapies available to address genomic alterations in MLL2.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MYD88", "Include": "true", "Alterations": {"Alteration": {"Name": "L265P", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "L265P"}}, "Interpretation": "MYD88 encodes a myeloid differentiation factor (Bonnert et al., 1997; 9013863), which functions as an adaptor protein in Toll_like receptor (TLR) signaling, a central component of the innate immune response (Medzhitov et al., 1998; 9734363). L265P is the most prevalent MYD88 mutation (Treon et al., 2012; 22931316, Ngo et al., 2011; 21179087); this mutation activates NFkB signaling (Avbelj et al., 2014; 25359991, Ngo et al., 2011; 21179087) and is frequently observed in patients with Waldenstrom s macroglobulinemia (WM) (Treon et al., 2012; 22931316) or activated B_cell_like subtype diffuse large B_cell lymphoma (ABC_DLBCL)(Ngo et al., 2011; 21179087). MYD88 activating mutations have been shown to predict response to ibrutinib in patients with WM, and clinical responses have been observed in patients with L265P or S243N mutations (Treon et al., 2015; 26244327, Treon et al., 2015; 25853747). MYD88 mutations have been reported in activated B_cell_like (ABC) subtype of diffuse large B_cell lymphoma (DLBCL, 30% of cases) (Ngo et al., 2011; 21179087, Choi et al., 2013; 23380077), 6% of marginal zone lymphoma, 5% of Burkitt lymphoma, 5% of MALT lymphoma, and 2% of follicular lymphoma cases (Xu et al., 2011; Blood 118:261)(Schmitz et al., 2012; 22885699, Rossi et al., 2012; 22891273, Li et al., 2012; 22640364). Somatic alteration of MYD88 is most frequently observed in Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (70_100% of cases) (Ansell et al., 2012; ASH Abstract 2699) (Treon and Hunter, 2013; 23723443, Poulain et al., 2013; 23532735, Treon et al., 2012; 22931316, Wang et al., 2021; 33735664). Although MYD88 L265P has been associated with increased bone marrow involvement and serum IgM levels in WM, particularly in the presence of a concurrent CXCR4 mutation, the MYD88 L265P mutation had a positive impact on overall survival compared to wild_type MYD88 (Treon et al., 2014; 24553177, Wang et al., 2021; 33735664). In another study, high levels of MYD88 expression correlated with decreased disease_free progression in patients with DLBCL (p=0.025) (Choi et al., 2013; 23380077). There are no available therapies that directly target MYD88. In preclinical studies, inhibitors of IRAK1/4 or BTK kinases exhibited antiproliferative effects on cells with an MYD88 activating mutation (Ngo et al., 2011; 21179087, Yang et al., 2012; J Clin Oncol 30:8106). BTK inhibitors showed antitumor activity for patients with MYD88_mutated diffuse large B_cell lymphoma, but only in the presence of a concurrent CD79B activating alteration (4/5 responses to ibrutinib for patients with concurrent MYD88 and CD79B mutations versus 0/7 for patients with MYD88 mutations and wildtype CD79B)(Roschewski et al., 2014; 24217204, Aalipour et al., 2013; 24111579). Multiple studies demonstrated numerically higher efficacy of zanubrutinib for patients with MYD88 L265P_mutated Waldenstrom macroglobulinemia (WM) than those with unmutated MYD88, although the studies were not powered to statistically compare the efficacy between the 2 groups (Tam et al., 2020; 32731259, Dimopoulos et al., 2021; 33284944, An et al., 2021; 34253577, Trotman et al., 2019; EHA Abstract PF481). A Phase 1/2 study evaluating pirtobrutinib to treat B_cell malignancies reported ORRs for patients with WM of 68% (13/19, with responses ongoing for 10/13), including for patients who had progressed on prior covalent BTK inhibitors (Mato et al., 2021; 33676628). In a Phase 1b/2 trial of the noncovalent BTK inhibitor vecabrutinib, no responses were observed for any of the 9 treated patients with hematologic malignancies (chronic lymphocytic leukemia [CLL], n=6; mantle cell lymphoma, n=3; WM, n=1), although these patients were only treated with a low dose (25_50 mg) as part of the dose escalation cohort (Allan et al., 2018; ASH Abstract 3141). The effect of MYD88 L265P on the efficacy of ibrutinib for patients with CLL is not yet clear (Aaliour and Advani, 2014; 25360238). CXCR4 inhibitors such as plerixafor (Domanska et al., 2013; 22683307) may be a suitable combination therapy with ibrutinib for patients with CXCR4 activation in addition to MYD88 activating mutations (Treon et al., 2014; 24553177, Cao et al., 2015; 25371371).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). High MSI (MSI_H) is generally rare in hematologic malignancies compared with solid tumors. Moreover, reports of MSI in hematologic malignancies in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, small sample size in most studies, and possible elimination of MSI_positive cells in the bloodstream by immunosurveillance (Maletzki et al., 2013; 24167765). Several small studies have observed MSI at any level in 12% (3/25) to 33% (5/15) of diffuse large B cell lymphoma (DLBCL) (Miyashita et al., 2008; 18177936, de Miranda et al., 2013; 23960188, Starostik et al., 2000; 11021817, Hiyama et al., 2001; 11182043, Jordanova et al., 2003; 12471623). MSI_H has been reported in ~3% of DLBCL cases in general (Borie et al., 2009; 19551857, Starostik et al., 2000; 11021817), in a patient with MALT lymphoma with a DLBCL component (Degroote et al., 2013; 22916837), and in two patients with hereditary non_polyposis colon cancer (HNPCC) who developed DLBCL (Pineda et al., 2008; 18181177, Cheah et al., 2015; 26008772). However, none (0/48) of the DLBCL cases in a computational analysis of paired tumor and normal cases in the TCGA dataset were MSI_H (Bonneville et al., 2017; 29850653), and another study of 70 DLBCL cases found no instances of MSI (Couronn\u00e9 et al., 2013; 23066952). In one study, the incidence of MSI in DLBCL was 7_fold higher compared with lower grade MALT lymphoma (p=0.009), suggesting that MSI frequency was associated with transition from low_ to high_grade disease (Starostik et al., 2000; 11021817). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PIM1", "Include": "true", "Alterations": {"Alteration": [{"Name": "Q127*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q127*"}}, "Interpretation": "PIM1 encodes a serine/threonine kinase that regulates cell survival and proliferation and cooperates with the MYC oncogene to promote lymphomagenesis (Blanco_Aparicio and Carnero et al., 2013; 23041228, Nawijin et al., 2011; 21150935, Wang et al., 2002; 12431783, Qian et al., 2005; 15525646, Kumar et al., 2005; 15808862, Amson et al., 1989; 2682662, van Lohuizen et al., 1989; 2537153). The PIM1 locus is subject to somatic hypermutation in lymphoid malignancies, including diffuse large B_cell lymphoma (DLBCL) (Pasqualucci et al., 2001; 11460166, Pasqualucci et al., 2011; 21804550, Georgiou et al., 2016; 27030389). PIM1 mutations also may contribute to the transformation of FL or chronic lymphocytic leukemia (CLL) to DLBCL (Rossi et al., 2006; 17018394, Halld\u00f3rsd\u00f3ttir et al., 2008; 18180034). Although a few mutations have been characterized in vitro as having an effect on PIM1 kinase activity (Kumar et al., 2005; 15808862), direct experimental evidence for any selectable advantage for somatically mutated PIM1 variants in lymphoma cells is lacking. Mutations in PIM1 have been reported in 1/9 of classic Hodgkin lymphoma (HL) and in 3/8 of nodular lymphocyte predominant HL (NLPHL) samples (Liso et al., 2006; 16614247) but have been more frequently reported in non_Hodgkin lymphoma (NHL), including 19_65% diffuse large B_cell lymphoma (DLBCL), 19_100% primary central nervous system lymphoma (PCNSL), 16% (5/32) of follicular lymphoma (FL), 35% (9/26) of FL transformed to DLBCL samples, 61.5% (8/13) of mucosa_associated lymphoid tissue_type (MALT) lymphomas, 9.5% (2/21) of nodal marginal zone B_cell lymphomas and in 1/11 primary cutaneous marginal zone B_cell lymphomas (PCMZL) (Pasqualucci et al., 2011; 21804550, Morin et al., 2011; 21796119, Schuetz et al., 2012; 22189900, Halld\u00f3rsd\u00f3ttir et al., 2008; 18180034, Deutsch et al., 2007; 17197434, Traverse_Glehen et al., 2007; 17476282, Fukumura et al., 2016; 26757737, Montesinos_Rongen et al., 2004; 14592832, Bruno et al., 2014; 24970810, Braggio et al., 2015; 25991819, Vater et al., 2015; 25189415). PIM1 kinase is predicted to be constitutively active, regulated primarily at the level of expression (Qian et al., 2005; 15525646, Kumar et al., 2005; 15808862, Nawijin et al., 2011; 21150935, Amson et al., 1989; 2682662). PIM1 expression has been reported in MCL, DLBCL, acute myeloid leukemia (AML) and B_cell acute lymphocytic leukemia (B_ALL) samples (Sivertsen et al., 2006; 16437153, Mhadevan et al., 2005; 16373702, , Brault et al., 2012; 22722314, Hsi et al., 2008; 19021050, Zhu et al., 2002; 12472567, Amson et al., 1989; 2682662, Mavilio et al., 1986; 3520570) and high expression has been reported to predict poor outcome in MCL and DLBCL (Hsi et al., 2008; 19021050, Sivertsen et al., 2006; 16437153, Nawijin et al., 2011; 21150935). Expression of PIM1 and/or PIM2 was also associated with poor prognosis in FL (Schatz et al., 2011; 21859846). There are no approved therapies that directly target PIM1 alterations, although PIM kinase inhibitors are in clinical development, primarily in hematologic malignancies (Shin et al., 2015; AACR Abstract 5397, Padi et al., 2017; 28415816, Arunesh et al., 2013; 24131033, Merkel et al., 2012; 22385334). In preclinical studies, expression PIM1 or other PIM kinases has been reported to activate the mTOR pathway (Zhang et al., 2009; 19276681, Beharry et al., 2011; 21187426). Although some preclinical studies have reported that PIM activation confers resistance to inhibitors of the PI3K_Akt_mTOR pathway (Blanco_Aparicio et al., 2013; ANE Abstract A275, Hammerman et al., 2005; 15705789, Walpen et al., 2012; 23131564), others have found that PIM_overexpressing cells are sensitive to mTOR inhibition (Zhang et al., 2009; 19276681, Beharry et al., 2009; 19509254). However, studies have consistently shown synergistic anti_proliferative effects of PIM inhibitors in combination with PI3K_Akt_mTOR pathway inhibitors (Blanco_Aparicio et al., 2013; ANE Abstract A275)(Zhang et al., 2009; 19276681, Beharry et al., 2009; 19509254), and such approaches may be relevant for tumors with PIM1 activation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}, {"Name": "L2F", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "L2F"}}, "Interpretation": "PIM1 encodes a serine/threonine kinase that regulates cell survival and proliferation and cooperates with the MYC oncogene to promote lymphomagenesis (Blanco_Aparicio and Carnero et al., 2013; 23041228, Nawijin et al., 2011; 21150935, Wang et al., 2002; 12431783, Qian et al., 2005; 15525646, Kumar et al., 2005; 15808862, Amson et al., 1989; 2682662, van Lohuizen et al., 1989; 2537153). The PIM1 locus is subject to somatic hypermutation in lymphoid malignancies, including diffuse large B_cell lymphoma (DLBCL) (Pasqualucci et al., 2001; 11460166, Pasqualucci et al., 2011; 21804550, Georgiou et al., 2016; 27030389). PIM1 mutations also may contribute to the transformation of FL or chronic lymphocytic leukemia (CLL) to DLBCL (Rossi et al., 2006; 17018394, Halld\u00f3rsd\u00f3ttir et al., 2008; 18180034). Although a few mutations have been characterized in vitro as having an effect on PIM1 kinase activity (Kumar et al., 2005; 15808862), direct experimental evidence for any selectable advantage for somatically mutated PIM1 variants in lymphoma cells is lacking. Mutations in PIM1 have been reported in 1/9 of classic Hodgkin lymphoma (HL) and in 3/8 of nodular lymphocyte predominant HL (NLPHL) samples (Liso et al., 2006; 16614247) but have been more frequently reported in non_Hodgkin lymphoma (NHL), including 19_65% diffuse large B_cell lymphoma (DLBCL), 19_100% primary central nervous system lymphoma (PCNSL), 16% (5/32) of follicular lymphoma (FL), 35% (9/26) of FL transformed to DLBCL samples, 61.5% (8/13) of mucosa_associated lymphoid tissue_type (MALT) lymphomas, 9.5% (2/21) of nodal marginal zone B_cell lymphomas and in 1/11 primary cutaneous marginal zone B_cell lymphomas (PCMZL) (Pasqualucci et al., 2011; 21804550, Morin et al., 2011; 21796119, Schuetz et al., 2012; 22189900, Halld\u00f3rsd\u00f3ttir et al., 2008; 18180034, Deutsch et al., 2007; 17197434, Traverse_Glehen et al., 2007; 17476282, Fukumura et al., 2016; 26757737, Montesinos_Rongen et al., 2004; 14592832, Bruno et al., 2014; 24970810, Braggio et al., 2015; 25991819, Vater et al., 2015; 25189415). PIM1 kinase is predicted to be constitutively active, regulated primarily at the level of expression (Qian et al., 2005; 15525646, Kumar et al., 2005; 15808862, Nawijin et al., 2011; 21150935, Amson et al., 1989; 2682662). PIM1 expression has been reported in MCL, DLBCL, acute myeloid leukemia (AML) and B_cell acute lymphocytic leukemia (B_ALL) samples (Sivertsen et al., 2006; 16437153, Mhadevan et al., 2005; 16373702, , Brault et al., 2012; 22722314, Hsi et al., 2008; 19021050, Zhu et al., 2002; 12472567, Amson et al., 1989; 2682662, Mavilio et al., 1986; 3520570) and high expression has been reported to predict poor outcome in MCL and DLBCL (Hsi et al., 2008; 19021050, Sivertsen et al., 2006; 16437153, Nawijin et al., 2011; 21150935). Expression of PIM1 and/or PIM2 was also associated with poor prognosis in FL (Schatz et al., 2011; 21859846). There are no approved therapies that directly target PIM1 alterations, although PIM kinase inhibitors are in clinical development, primarily in hematologic malignancies (Shin et al., 2015; AACR Abstract 5397, Padi et al., 2017; 28415816, Arunesh et al., 2013; 24131033, Merkel et al., 2012; 22385334). In preclinical studies, expression PIM1 or other PIM kinases has been reported to activate the mTOR pathway (Zhang et al., 2009; 19276681, Beharry et al., 2011; 21187426). Although some preclinical studies have reported that PIM activation confers resistance to inhibitors of the PI3K_Akt_mTOR pathway (Blanco_Aparicio et al., 2013; ANE Abstract A275, Hammerman et al., 2005; 15705789, Walpen et al., 2012; 23131564), others have found that PIM_overexpressing cells are sensitive to mTOR inhibition (Zhang et al., 2009; 19276681, Beharry et al., 2009; 19509254). However, studies have consistently shown synergistic anti_proliferative effects of PIM inhibitors in combination with PI3K_Akt_mTOR pathway inhibitors (Blanco_Aparicio et al., 2013; ANE Abstract A275)(Zhang et al., 2009; 19276681, Beharry et al., 2009; 19509254), and such approaches may be relevant for tumors with PIM1 activation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}]}, "ReferenceLinks": null}, {"Name": "VHL", "Include": "true", "Alterations": {"Alteration": {"Name": "R200W", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R200W"}}, "Interpretation": "VHL encodes the protein pVHL (von Hippel_Lindau tumor suppressor), which is frequently inactivated, either via mutation or hypermethylation, in clear cell renal cell carcinoma (ccRCC) and plays an important role in its pathogenesis (Li and Kaelin, 2011; 21763962). Inactivating mutations in VHL lead to dysregulation of critical downstream growth regulators, especially members of the HIF family and VEGF (Kaelin and Ratcliffe, 2008; 18498744, Gnarra et al., 1996; 8855222). Alterations such as seen here may disrupt VHL function or expression (Albers et al., 2013; 23606570, Asakawa et al., 2012; 22462637, Banks et al., 2006; 16488999, Bond et al., 2011; 21454469, Clifford et al., 2001; 11331613, Cockman et al., 2000; 10823831, Corn et al., 2003; 14556007, Dandanell et al., 2012; 22799452, Feldman et al., 1999; 10635329, Feldman et al., 2003; 14636579, Hansen et al., 2002; 11865071, Hoffman et al., 2001; 11331612, Khacho et al., 2008; 17967880, Kibel et al., 1995; 7660130, Knauth et al., 2006; 16261165, Lewis and Roberts., 2004; 14691445, Li et al., 2002; 11739384, Li et al., 2002; 12056827, Liu and Nussinov, 2009; 19798438, Losonczy et al., 2013; 23298237, Maher et al., 1996; 8730290, McClellan et al., 2005; 15935760, Metzger and Michaelis, 2009; 19073890, Miller et al., 2005; 15611064, Moore et al., 2011; 22022277, Neumann et al., 1995; 7563486, Ohh et al., 1999; 10587522, Ohh et al., 2000; 10878807, Olschwang et al., 1998; 9829912, Patocs et al., 2008; 18416845, Rechsteiner et al., 2011; 21715564, Richards, 2001; 14987375, Ritter et al., 1996; 8772572, Schoenfeld et al., 2000; 10900011, Shmueli et al., 2013; 23840444, Siu et al., 2011; 21362373, Weirich et al., 2002; 12414898, Zbar et al., 1996; 8956040, Zhou et al., 2004; 14973063). VHL mutations are extremely rare in leukemias and lymphomas. VHL mutations were reported in <0.5% of hematological and lymphoid malignancies in COSMIC (Jan 2021). Reduced expression of VHL, mediated by promoter hypermethylation or targeting by microRNAs, has been reported in chronic lymphoid leukemia and associated with poor prognosis (Kanduri et al., 2010; 19897574, Ghosh et al., 2009; 19336759). Similarly, hypermethylation of VHL has been associated with reduced survival and disease_free survival in one study of diffuse large B_cell lymphoma (Amara et al., 2008; 18539616), although the functional relevance of this is unclear (Kalac et al., 2011; 21772049). Various strategies are under clinical investigation to block pathways downstream of inactivated VHL, including HIF, VEGF, and mTOR. The multikinase inhibitor sunitinib, which has activity against VEGFRs and other targets, is approved to treat several tumor types and has shown strong efficacy in patients with VHL disease (Jimenez et al., 2009; 19017755, Kim et al., 2013; 24454008, Tsimafeyeu, 2015; 26881543, Babinska et al., 2015; 26812297, Kobayashi et al., 2016; 26984080). Several clinical trials found response rates up to 64% and disease control rates up to 90% (Matin et al., 2010; ASCO Abstract 3040, Jonasch et al., 2011; 22105611, Roma et al., 2015; 25391617). However, multiple clinical studies of sunitinib in patients with renal cell carcinoma reported that mutation or inactivation of the VHL gene is not significantly associated with therapeutic response or survival (Saez et al., 2012; ASCO Abstract 4630, Rini et al., 2006; 16827904, Choueiri et al., 2008; 18635227, Motzeret al., 2014; 25100134). Other agents that inhibit VEGFRs, including the multikinase inhibitors sorafenib, axitinib, pazopanib, regorafenib, cabozantinib, and vandetanib; the anti_VEGFR2 antibody ramucirumab; and the mTOR inhibitors everolimus and temsirolimus, are also approved in multiple tumor types. However, studies have similarly shown that VHL mutation or inactivation does not correlate with responses to these agents (Hutson et al., 2008; ASCO Abstract 5046, Choueiri et al., 2008; 18635227, Cho et al., 2007; 17956710, Choueiri et al., 2013; 23881929). Therefore, it is unclear whether these therapeutic strategies would be beneficial in this case. The HIF2a inhibitor belzutifan achieved an ORR of 36% in a clinical trial for VHL disease_associated clear cell renal cell carcinoma (Srinivasan et al., 2021; ASCO Abstract 4555). Responses were also seen in other VHL mutation_associated tumor types, including CNS hemangioblastomas and pancreatic neuroendocrine tumors; however, it was not determined whether VHL inactivation was significantly associated with these responses (Srinivasan et al., 2021; ASCO Abstract 4555). One or more of the VHL variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with von Hippel_Lindau syndrome (ClinVar, Sep 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Inactivating germline mutations in VHL underlie von Hippel_Lindau syndrome, a rare but highly penetrant autosomal dominant syndrome occurring in 1/36,000 live births that predisposes to the development of several types of cancer, including clear cell renal cell carcinomas and pancreatic neuroendocrine tumors, as well as retinal and central nervous system hemangioblastomas (Maher et al., 2011; 21386872, Haddad et al., 2013; 24138046, Richard et al., 2013; 22659535). In the appropriate clinical context, germline testing of VHL is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab", "StudyPhase": "PHASE 1/2", "Target": "PD_1, CCR4", "Locations": "Taipei (Taiwan), Tainan (Taiwan), Shatin (Hong Kong), High West (Hong Kong), Ulsan (Korea, Republic of), Chungbuk (Korea, Republic of), Seoul (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia), Heidelberg (Australia)", "NCTID": "NCT03674567", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non_Hodgkin Lymphoma", "StudyPhase": "PHASE 2", "Target": "PD_1, ADORA2A", "Locations": "Taipei (Taiwan), Koto ku (Japan), Singapore (Singapore), Brno (Czechia), Salzburg (Austria), Essen (Germany), Koeln (Germany), St. Gallen (Switzerland), Rotterdam (Netherlands), Liege (Belgium)", "NCTID": "NCT03207867", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "StudyPhase": "PHASE 1", "Target": "PD_1", "Locations": "Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Leuven (Belgium), Barcelona (Spain), California, Texas", "NCTID": "NCT04261439", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL", "StudyPhase": "PHASE 1/2", "Target": "RET, VEGFR2, PD_1", "Locations": "Guangzhou (China)", "NCTID": "NCT04476459", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "A Safety and Pharmacokinetic Study of BTCT4465A, With or Without Single_dose Obinutuzumab Pretreatment, in Non_Hodgkin s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)", "StudyPhase": "PHASE 1/2", "Target": "PD_L1, CD20, CD3", "Locations": "Seoul (Korea, Republic of), Nedlands (Australia), South Brisbane (Australia), Woolloongabba (Australia), Adelaide (Australia), Darlinghurst (Australia), Fitzroy (Australia), Melbourne (Australia), Clayton (Australia), Hobart (Australia)", "NCTID": "NCT02500407", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "Study of REGN3767 (Anti_LAG_3) With or Without REGN2810 (Anti_PD1) in Advanced Cancers", "StudyPhase": "PHASE 1", "Target": "PD_1, LAG_3", "Locations": "Seoul (Korea, Republic of), Perth (Australia), Brisbane (Australia), Melbourne (Australia), London (United Kingdom), Headington (United Kingdom), Dublin (Ireland), California", "NCTID": "NCT03005782", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)", "StudyPhase": "PHASE 2", "Target": "PD_1", "Locations": "Beijing (China)", "NCTID": "NCT04070040", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma", "StudyPhase": "PHASE null", "Target": "PD_1, CD30", "Locations": "Washington", "NCTID": "NCT01703949", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "22", "Title": "Feasibility Study of Induction and Maintenance Avelumab Plus R_CHOP in Patients With Diffuse DLBCL: The AvR_CHOP Study", "StudyPhase": "PHASE null", "Target": "PD_L1, CD20", "Locations": "Ballarat (Australia), Heidelberg (Australia), Box Hill (Australia)", "NCTID": "NCT03244176", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors. As it is unclear whether TMB is associated with efficacy in hematological malignancies, it is not known whether these therapeutic strategies would be relevant here.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "1", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "2", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "3", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "4", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "5", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "6", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "7", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "8", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "9", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "10", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "11", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "12", "ReferenceId": "14592832", "FullCitation": "Montesinos_Rongen M, et al. Blood (2004) pmid: 14592832", "Include": "true"}, {"number": "13", "ReferenceId": "25383641", "FullCitation": "Montesinos_Rongen M, et al. J. Neuropathol. Exp. Neurol. (2014) pmid: 25383641", "Include": "true"}, {"number": "14", "ReferenceId": "25189415", "FullCitation": "Vater I, et al. Leukemia (2015) pmid: 25189415", "Include": "true"}, {"number": "15", "ReferenceId": "10477699", "FullCitation": "Thompsett AR, et al. Blood (1999) pmid: 10477699", "Include": "true"}, {"number": "16", "ReferenceId": "24240734", "FullCitation": "Deckert M, et al. Acta Neuropathol. (2014) pmid: 24240734", "Include": "true"}, {"number": "17", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "18", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "19", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "20", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "21", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "22", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "23", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "24", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "25", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "26", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "27", "ReferenceId": "21763962", "FullCitation": "Li L, et al. Hematol. Oncol. Clin. North Am. (2011) pmid: 21763962", "Include": "true"}, {"number": "28", "ReferenceId": "18498744", "FullCitation": "Kaelin WG, et al. Mol. Cell (2008) pmid: 18498744", "Include": "true"}, {"number": "29", "ReferenceId": "8855222", "FullCitation": "Gnarra JR, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8855222", "Include": "true"}, {"number": "30", "ReferenceId": "23606570", "FullCitation": "Albers J, et al. EMBO Mol Med (2013) pmid: 23606570", "Include": "true"}, {"number": "31", "ReferenceId": "22462637", "FullCitation": "Asakawa T, et al. BMC Med. Genet. (2012) pmid: 22462637", "Include": "true"}, {"number": "32", "ReferenceId": "16488999", "FullCitation": "Banks RE, et al. Cancer Res. (2006) pmid: 16488999", "Include": "true"}, {"number": "33", "ReferenceId": "21454469", "FullCitation": "Bond J, et al. Blood (2011) pmid: 21454469", "Include": "true"}, {"number": "34", "ReferenceId": "11331613", "FullCitation": "Clifford SC, et al. Hum. Mol. Genet. (2001) pmid: 11331613", "Include": "true"}, {"number": "35", "ReferenceId": "10823831", "FullCitation": "Cockman ME, et al. J. Biol. Chem. (2000) pmid: 10823831", "Include": "true"}, {"number": "36", "ReferenceId": "14556007", "FullCitation": "Corn PG, et al. Nat. Genet. (2003) pmid: 14556007", "Include": "true"}, {"number": "37", "ReferenceId": "22799452", "FullCitation": "Dandanell M, et al. BMC Med. Genet. (2012) pmid: 22799452", "Include": "true"}, {"number": "38", "ReferenceId": "10635329", "FullCitation": "Feldman DE, et al. Mol. Cell (1999) pmid: 10635329", "Include": "true"}, {"number": "39", "ReferenceId": "14636579", "FullCitation": "Feldman DE, et al. Mol. Cell (2003) pmid: 14636579", "Include": "true"}, {"number": "40", "ReferenceId": "11865071", "FullCitation": "Hansen WJ, et al. Mol. Cell. Biol. (2002) pmid: 11865071", "Include": "true"}, {"number": "41", "ReferenceId": "11331612", "FullCitation": "Hoffman MA, et al. Hum. Mol. Genet. (2001) pmid: 11331612", "Include": "true"}, {"number": "42", "ReferenceId": "17967880", "FullCitation": "Khacho M, et al. Mol. Cell. Biol. (2008) pmid: 17967880", "Include": "true"}, {"number": "43", "ReferenceId": "7660130", "FullCitation": "Kibel A, et al. Science (1995) pmid: 7660130", "Include": "true"}, {"number": "44", "ReferenceId": "16261165", "FullCitation": "Knauth K, et al. Oncogene (2006) pmid: 16261165", "Include": "true"}, {"number": "45", "ReferenceId": "14691445", "FullCitation": "Lewis MD, et al. Oncogene (2004) pmid: 14691445", "Include": "true"}, {"number": "46", "ReferenceId": "11739384", "FullCitation": "Li Z, et al. J. Biol. Chem. (2002) pmid: 11739384", "Include": "true"}, {"number": "47", "ReferenceId": "12056827", "FullCitation": "Li Z, et al. Biochem. Biophys. Res. Commun. (2002) pmid: 12056827", "Include": "true"}, {"number": "48", "ReferenceId": "19798438", "FullCitation": "Liu J, et al. PLoS Comput. Biol. (2009) pmid: 19798438", "Include": "true"}, {"number": "49", "ReferenceId": "23298237", "FullCitation": "Losonczy G, et al. BMC Med. Genet. (2013) pmid: 23298237", "Include": "true"}, {"number": "50", "ReferenceId": "8730290", "FullCitation": "Maher ER, et al. J. Med. Genet. (1996) pmid: 8730290", "Include": "true"}, {"number": "51", "ReferenceId": "15935760", "FullCitation": "McClellan AJ, et al. Cell (2005) pmid: 15935760", "Include": "true"}, {"number": "52", "ReferenceId": "19073890", "FullCitation": "Metzger MB, et al. Mol. Biol. Cell (2009) pmid: 19073890", "Include": "true"}, {"number": "53", "ReferenceId": "15611064", "FullCitation": "Miller F, et al. J. Biol. Chem. (2005) pmid: 15611064", "Include": "true"}, {"number": "54", "ReferenceId": "22022277", "FullCitation": "Moore LE, et al. PLoS Genet. (2011) pmid: 22022277", "Include": "true"}, {"number": "55", "ReferenceId": "7563486", "FullCitation": "Neumann HP, et al. JAMA (1995) pmid: 7563486", "Include": "true"}, {"number": "56", "ReferenceId": "10587522", "FullCitation": "Ohh M, et al. J. Clin. Invest. (1999) pmid: 10587522", "Include": "true"}, {"number": "57", "ReferenceId": "10878807", "FullCitation": "Ohh M, et al. Nat. Cell Biol. (2000) pmid: 10878807", "Include": "true"}, {"number": "58", "ReferenceId": "9829912", "FullCitation": "Olschwang S, et al. Hum. Mutat. (1998) pmid: 9829912", "Include": "true"}, {"number": "59", "ReferenceId": "18416845", "FullCitation": "Patocs A, et al. BMC Med. Genet. (2008) pmid: 18416845", "Include": "true"}, {"number": "60", "ReferenceId": "21715564", "FullCitation": "Rechsteiner MP, et al. Cancer Res. (2011) pmid: 21715564", "Include": "true"}, {"number": "61", "ReferenceId": "14987375", "FullCitation": "Expert Rev Mol Med (2001) pmid: 14987375", "Include": "true"}, {"number": "62", "ReferenceId": "8772572", "FullCitation": "Ritter MM, et al. J. Clin. Endocrinol. Metab. (1996) pmid: 8772572", "Include": "true"}, {"number": "63", "ReferenceId": "10900011", "FullCitation": "Schoenfeld AR, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10900011", "Include": "true"}, {"number": "64", "ReferenceId": "23840444", "FullCitation": "Shmueli MD, et al. PLoS ONE (2013) pmid: 23840444", "Include": "true"}, {"number": "65", "ReferenceId": "21362373", "FullCitation": "Siu WK, et al. Chin. Med. J. (2011) pmid: 21362373", "Include": "true"}, {"number": "66", "ReferenceId": "12414898", "FullCitation": "Weirich G, et al. J. Clin. Endocrinol. Metab. (2002) pmid: 12414898", "Include": "true"}, {"number": "67", "ReferenceId": "8956040", "FullCitation": "Zbar B, et al. Hum. Mutat. (1996) pmid: 8956040", "Include": "true"}, {"number": "68", "ReferenceId": "14973063", "FullCitation": "Zhou MI, et al. Cancer Res. (2004) pmid: 14973063", "Include": "true"}, {"number": "69", "ReferenceId": "19897574", "FullCitation": "Kanduri M, et al. Blood (2010) pmid: 19897574", "Include": "true"}, {"number": "70", "ReferenceId": "19336759", "FullCitation": "Ghosh AK, et al. Blood (2009) pmid: 19336759", "Include": "true"}, {"number": "71", "ReferenceId": "18539616", "FullCitation": "Amara K, et al. Ann. Oncol. (2008) pmid: 18539616", "Include": "true"}, {"number": "72", "ReferenceId": "21772049", "FullCitation": "Kalac M, et al. Blood (2011) pmid: 21772049", "Include": "true"}, {"number": "73", "ReferenceId": "19017755", "FullCitation": "Jimenez C, et al. J. Clin. Endocrinol. Metab. (2009) pmid: 19017755", "Include": "true"}, {"number": "74", "ReferenceId": "24454008", "FullCitation": "Kim HC, et al. Cancer Res Treat (2013) pmid: 24454008", "Include": "true"}, {"number": "75", "ReferenceId": "26881543", "FullCitation": "J Cancer Res Ther () pmid: 26881543", "Include": "true"}, {"number": "76", "ReferenceId": "26812297", "FullCitation": "Babinska A, et al. Neuro Endocrinol. Lett. (2015) pmid: 26812297", "Include": "true"}, {"number": "77", "ReferenceId": "26984080", "FullCitation": "Kobayashi A, et al. Intern. Med. (2016) pmid: 26984080", "Include": "true"}, {"number": "78", "ReferenceId": "22105611", "FullCitation": "Jonasch E, et al. Ann. Oncol. (2011) pmid: 22105611", "Include": "true"}, {"number": "79", "ReferenceId": "25391617", "FullCitation": "Roma A, et al. Fam. Cancer (2015) pmid: 25391617", "Include": "true"}, {"number": "80", "ReferenceId": "16827904", "FullCitation": "Rini BI, et al. BJU Int. (2006) pmid: 16827904", "Include": "true"}, {"number": "81", "ReferenceId": "18635227", "FullCitation": "Choueiri TK, et al. J. Urol. (2008) pmid: 18635227", "Include": "true"}, {"number": "82", "ReferenceId": "25100134", "FullCitation": "Motzer RJ, et al. Cancer Chemother. Pharmacol. (2014) pmid: 25100134", "Include": "true"}, {"number": "83", "ReferenceId": "17956710", "FullCitation": "Cho D, et al. Clin Genitourin Cancer (2007) pmid: 17956710", "Include": "true"}, {"number": "84", "ReferenceId": "23881929", "FullCitation": "Choueiri TK, et al. Clin. Cancer Res. (2013) pmid: 23881929", "Include": "true"}, {"number": "85", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "86", "ReferenceId": "21386872", "FullCitation": "Maher ER, et al. Eur. J. Hum. Genet. (2011) pmid: 21386872", "Include": "true"}, {"number": "87", "ReferenceId": "24138046", "FullCitation": "Haddad NM, et al. Semin Ophthalmol () pmid: 24138046", "Include": "true"}, {"number": "88", "ReferenceId": "22659535", "FullCitation": "Richard S, et al. Semin. Cancer Biol. (2013) pmid: 22659535", "Include": "true"}, {"number": "89", "ReferenceId": "23041228", "FullCitation": "Blanco_Aparicio C, et al. Biochem. Pharmacol. (2013) pmid: 23041228", "Include": "true"}, {"number": "90", "ReferenceId": "21150935", "FullCitation": "Nawijn MC, et al. Nat. Rev. Cancer (2011) pmid: 21150935", "Include": "true"}, {"number": "91", "ReferenceId": "12431783", "FullCitation": "Wang Z, et al. Biochim. Biophys. Acta (2002) pmid: 12431783", "Include": "true"}, {"number": "92", "ReferenceId": "15525646", "FullCitation": "Qian KC, et al. J. Biol. Chem. (2005) pmid: 15525646", "Include": "true"}, {"number": "93", "ReferenceId": "15808862", "FullCitation": "Kumar A, et al. J. Mol. Biol. (2005) pmid: 15808862", "Include": "true"}, {"number": "94", "ReferenceId": "2682662", "FullCitation": "Amson R, et al. Proc. Natl. Acad. Sci. U.S.A. (1989) pmid: 2682662", "Include": "true"}, {"number": "95", "ReferenceId": "2537153", "FullCitation": "van Lohuizen M, et al. Cell (1989) pmid: 2537153", "Include": "true"}, {"number": "96", "ReferenceId": "11460166", "FullCitation": "Pasqualucci L, et al. Nature (2001) pmid: 11460166", "Include": "true"}, {"number": "97", "ReferenceId": "21804550", "FullCitation": "Pasqualucci L, et al. Nat. Genet. (2011) pmid: 21804550", "Include": "true"}, {"number": "98", "ReferenceId": "27030389", "FullCitation": "Georgiou K, et al. Blood (2016) pmid: 27030389", "Include": "true"}, {"number": "99", "ReferenceId": "17018394", "FullCitation": "Rossi D, et al. Haematologica (2006) pmid: 17018394", "Include": "true"}, {"number": "100", "ReferenceId": "18180034", "FullCitation": "Halld\u00f3rsd\u00f3ttir AM, et al. Leuk. Res. (2008) pmid: 18180034", "Include": "true"}, {"number": "101", "ReferenceId": "16614247", "FullCitation": "Liso A, et al. Blood (2006) pmid: 16614247", "Include": "true"}, {"number": "102", "ReferenceId": "21796119", "FullCitation": "Morin RD, et al. Nature (2011) pmid: 21796119", "Include": "true"}, {"number": "103", "ReferenceId": "22189900", "FullCitation": "Schuetz JM, et al. Leukemia (2012) pmid: 22189900", "Include": "true"}, {"number": "104", "ReferenceId": "17197434", "FullCitation": "Deutsch AJ, et al. Blood (2007) pmid: 17197434", "Include": "true"}, {"number": "105", "ReferenceId": "17476282", "FullCitation": "Traverse_Glehen A, et al. Leukemia (2007) pmid: 17476282", "Include": "true"}, {"number": "106", "ReferenceId": "26757737", "FullCitation": "Fukumura K, et al. Acta Neuropathol. (2016) pmid: 26757737", "Include": "true"}, {"number": "107", "ReferenceId": "24970810", "FullCitation": "Bruno A, et al. Oncotarget (2014) pmid: 24970810", "Include": "true"}, {"number": "108", "ReferenceId": "25991819", "FullCitation": "Braggio E, et al. Clin. Cancer Res. (2015) pmid: 25991819", "Include": "true"}, {"number": "109", "ReferenceId": "16437153", "FullCitation": "Sivertsen EA, et al. Leukemia (2006) pmid: 16437153", "Include": "true"}, {"number": "110", "ReferenceId": "16373702", "FullCitation": "Mahadevan D, et al. Mol. Cancer Ther. (2005) pmid: 16373702", "Include": "true"}, {"number": "111", "ReferenceId": "22722314", "FullCitation": "Brault L, et al. Br. J. Cancer (2012) pmid: 22722314", "Include": "true"}, {"number": "112", "ReferenceId": "19021050", "FullCitation": "Hsi ED, et al. Leuk. Lymphoma (2008) pmid: 19021050", "Include": "true"}, {"number": "113", "ReferenceId": "12472567", "FullCitation": "Zhu Y, et al. Br. J. Haematol. (2002) pmid: 12472567", "Include": "true"}, {"number": "114", "ReferenceId": "3520570", "FullCitation": "Mavilio F, et al. Proc. Natl. Acad. Sci. U.S.A. (1986) pmid: 3520570", "Include": "true"}, {"number": "115", "ReferenceId": "21859846", "FullCitation": "Schatz JH, et al. J. Exp. Med. (2011) pmid: 21859846", "Include": "true"}, {"number": "116", "ReferenceId": "28415816", "FullCitation": "Padi SKR, et al. Oncotarget (2017) pmid: 28415816", "Include": "true"}, {"number": "117", "ReferenceId": "24131033", "FullCitation": "Arunesh GM, et al. Expert Opin Ther Pat (2014) pmid: 24131033", "Include": "true"}, {"number": "118", "ReferenceId": "22385334", "FullCitation": "Merkel AL, et al. Expert Opin Investig Drugs (2012) pmid: 22385334", "Include": "true"}, {"number": "119", "ReferenceId": "19276681", "FullCitation": "Zhang F, et al. Cancer Biol. Ther. (2009) pmid: 19276681", "Include": "true"}, {"number": "120", "ReferenceId": "21187426", "FullCitation": "Beharry Z, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21187426", "Include": "true"}, {"number": "121", "ReferenceId": "15705789", "FullCitation": "Hammerman PS, et al. Blood (2005) pmid: 15705789", "Include": "true"}, {"number": "122", "ReferenceId": "23131564", "FullCitation": "Walpen T, et al. Biochem. Biophys. Res. Commun. (2012) pmid: 23131564", "Include": "true"}, {"number": "123", "ReferenceId": "19509254", "FullCitation": "Beharry Z, et al. Mol. Cancer Ther. (2009) pmid: 19509254", "Include": "true"}, {"number": "124", "ReferenceId": "9013863", "FullCitation": "Bonnert TP, et al. FEBS Lett. (1997) pmid: 9013863", "Include": "true"}, {"number": "125", "ReferenceId": "9734363", "FullCitation": "Medzhitov R, et al. Mol. Cell (1998) pmid: 9734363", "Include": "true"}, {"number": "126", "ReferenceId": "22931316", "FullCitation": "Treon SP, et al. N. Engl. J. Med. (2012) pmid: 22931316", "Include": "true"}, {"number": "127", "ReferenceId": "21179087", "FullCitation": "Ngo VN, et al. Nature (2011) pmid: 21179087", "Include": "true"}, {"number": "128", "ReferenceId": "25359991", "FullCitation": "Avbelj M, et al. Blood (2014) pmid: 25359991", "Include": "true"}, {"number": "129", "ReferenceId": "26244327", "FullCitation": "Treon SP, et al. N. Engl. J. Med. (2015) pmid: 26244327", "Include": "true"}, {"number": "130", "ReferenceId": "25853747", "FullCitation": "Treon SP, et al. N. Engl. J. Med. (2015) pmid: 25853747", "Include": "true"}, {"number": "131", "ReferenceId": "23380077", "FullCitation": "Choi JW, et al. Hum. Pathol. (2013) pmid: 23380077", "Include": "true"}, {"number": "132", "ReferenceId": "22885699", "FullCitation": "Schmitz R, et al. Nature (2012) pmid: 22885699", "Include": "true"}, {"number": "133", "ReferenceId": "22891273", "FullCitation": "Rossi D, et al. J. Exp. Med. (2012) pmid: 22891273", "Include": "true"}, {"number": "134", "ReferenceId": "22640364", "FullCitation": "Li ZM, et al. Br. J. Haematol. (2012) pmid: 22640364", "Include": "true"}, {"number": "135", "ReferenceId": "23723443", "FullCitation": "Treon SP, et al. Blood (2013) pmid: 23723443", "Include": "true"}, {"number": "136", "ReferenceId": "23532735", "FullCitation": "Poulain S, et al. Blood (2013) pmid: 23532735", "Include": "true"}, {"number": "137", "ReferenceId": "33735664", "FullCitation": "Wang Y, et al. Neoplasia (2021) pmid: 33735664", "Include": "true"}, {"number": "138", "ReferenceId": "24553177", "FullCitation": "Treon SP, et al. Blood (2014) pmid: 24553177", "Include": "true"}, {"number": "139", "ReferenceId": "24217204", "FullCitation": "Roschewski M, et al. Nat Rev Clin Oncol (2014) pmid: 24217204", "Include": "true"}, {"number": "140", "ReferenceId": "24111579", "FullCitation": "Aalipour A, et al. Br. J. Haematol. (2013) pmid: 24111579", "Include": "true"}, {"number": "141", "ReferenceId": "32731259", "FullCitation": "Tam CS, et al. Blood (2020) pmid: 32731259", "Include": "true"}, {"number": "142", "ReferenceId": "33284944", "FullCitation": "Dimopoulos M, et al. Blood Adv (2020) pmid: 33284944", "Include": "true"}, {"number": "143", "ReferenceId": "34253577", "FullCitation": "An G, et al. Clin Cancer Res (2021) pmid: 34253577", "Include": "true"}, {"number": "144", "ReferenceId": "33676628", "FullCitation": "Mato AR, et al. Lancet (2021) pmid: 33676628", "Include": "true"}, {"number": "145", "ReferenceId": "25360238", "FullCitation": "Aalipour A, et al. Ther Adv Hematol (2014) pmid: 25360238", "Include": "true"}, {"number": "146", "ReferenceId": "22683307", "FullCitation": "Domanska UM, et al. Eur. J. Cancer (2013) pmid: 22683307", "Include": "true"}, {"number": "147", "ReferenceId": "25371371", "FullCitation": "Cao Y, et al. Br. J. Haematol. (2015) pmid: 25371371", "Include": "true"}, {"number": "148", "ReferenceId": "21447625", "FullCitation": "Vicent GP, et al. Genes Dev. (2011) pmid: 21447625", "Include": "true"}, {"number": "149", "ReferenceId": "21671394", "FullCitation": "Hannibal MC, et al. Am. J. Med. Genet. A (2011) pmid: 21671394", "Include": "true"}, {"number": "150", "ReferenceId": "31128216", "FullCitation": "Fagan RJ, et al. Cancer Lett. (2019) pmid: 31128216", "Include": "true"}, {"number": "151", "ReferenceId": "26722499", "FullCitation": "Ye H, et al. Int J Clin Exp Pathol (2015) pmid: 26722499", "Include": "true"}, {"number": "152", "ReferenceId": "22137796", "FullCitation": "Challa_Malladi M, et al. Cancer Cell (2011) pmid: 22137796", "Include": "true"}, {"number": "153", "ReferenceId": "22833104", "FullCitation": "Bernal M, et al. Cancer Immunol. Immunother. (2012) pmid: 22833104", "Include": "true"}, {"number": "154", "ReferenceId": "25488972", "FullCitation": "Reichel J, et al. Blood (2015) pmid: 25488972", "Include": "true"}, {"number": "155", "ReferenceId": "11894933", "FullCitation": "Rosa F, et al. EMBO J. (1983) pmid: 11894933", "Include": "true"}, {"number": "156", "ReferenceId": "25171927", "FullCitation": "de Miranda NF, et al. Blood (2014) pmid: 25171927", "Include": "true"}, {"number": "157", "ReferenceId": "25325033", "FullCitation": "Yoo C, et al. Blood Res (2014) pmid: 25325033", "Include": "true"}, {"number": "158", "ReferenceId": "6189572", "FullCitation": "Hagberg H, et al. Cancer (1983) pmid: 6189572", "Include": "true"}, {"number": "159", "ReferenceId": "25142947", "FullCitation": "Nakajima Y, et al. Med. Oncol. (2014) pmid: 25142947", "Include": "true"}, {"number": "160", "ReferenceId": "16545870", "FullCitation": "Albitar M, et al. Leuk. Res. (2007) pmid: 16545870", "Include": "true"}, {"number": "161", "ReferenceId": "8471438", "FullCitation": "Johnson PW, et al. Br. J. Cancer (1993) pmid: 8471438", "Include": "true"}, {"number": "162", "ReferenceId": "18024396", "FullCitation": "Federico M, et al. Haematologica (2007) pmid: 18024396", "Include": "true"}, {"number": "163", "ReferenceId": "19652063", "FullCitation": "Federico M, et al. J. Clin. Oncol. (2009) pmid: 19652063", "Include": "true"}, {"number": "164", "ReferenceId": "24180329", "FullCitation": "Proch\u00e1zka V, et al. Leuk. Lymphoma (2014) pmid: 24180329", "Include": "true"}, {"number": "165", "ReferenceId": "26350140", "FullCitation": "Miyashita K, et al. Leuk. Res. (2015) pmid: 26350140", "Include": "true"}, {"number": "166", "ReferenceId": "25689467", "FullCitation": "Yoo C, et al. Hematol Oncol (2016) pmid: 25689467", "Include": "true"}, {"number": "167", "ReferenceId": "22373550", "FullCitation": "Li ZM, et al. Ann. Hematol. (2012) pmid: 22373550", "Include": "true"}, {"number": "168", "ReferenceId": "24441948", "FullCitation": "Yoo C, et al. Ann. Hematol. (2014) pmid: 24441948", "Include": "true"}, {"number": "169", "ReferenceId": "2405920", "FullCitation": "Durie BG, et al. Blood (1990) pmid: 2405920", "Include": "true"}, {"number": "170", "ReferenceId": "20198709", "FullCitation": "Rossi D, et al. Cancer (2010) pmid: 20198709", "Include": "true"}, {"number": "171", "ReferenceId": "9215838", "FullCitation": "Tricot G, et al. J. Clin. Oncol. (1997) pmid: 9215838", "Include": "true"}, {"number": "172", "ReferenceId": "18022010", "FullCitation": "Stella_Holowiecka B, et al. Transplant. Proc. (2007) pmid: 18022010", "Include": "true"}, {"number": "173", "ReferenceId": "3907332", "FullCitation": "Alexanian R, et al. Am. J. Hematol. (1985) pmid: 3907332", "Include": "true"}, {"number": "174", "ReferenceId": "9645572", "FullCitation": "Barlogie B, et al. Bone Marrow Transplant. (1998) pmid: 9645572", "Include": "true"}, {"number": "175", "ReferenceId": "11841419", "FullCitation": "Tricot G, et al. Br. J. Haematol. (2002) pmid: 11841419", "Include": "true"}, {"number": "176", "ReferenceId": "17325847", "FullCitation": "Prince HM, et al. Leuk. Lymphoma (2007) pmid: 17325847", "Include": "true"}, {"number": "177", "ReferenceId": "12738677", "FullCitation": "Gatto S, et al. Blood (2003) pmid: 12738677", "Include": "true"}, {"number": "178", "ReferenceId": "18639338", "FullCitation": "Neumann F, et al. Leuk. Res. (2009) pmid: 18639338", "Include": "true"}, {"number": "179", "ReferenceId": "1405762", "FullCitation": "Melillo L, et al. Leukemia (1992) pmid: 1405762", "Include": "true"}, {"number": "180", "ReferenceId": "1466355", "FullCitation": "Kantarjian HM, et al. Am. J. Med. (1992) pmid: 1466355", "Include": "true"}, {"number": "181", "ReferenceId": "24547751", "FullCitation": "Shvidel L, et al. Eur. J. Haematol. (2014) pmid: 24547751", "Include": "true"}, {"number": "182", "ReferenceId": "18931340", "FullCitation": "Dhodapkar MV, et al. Blood (2009) pmid: 18931340", "Include": "true"}, {"number": "183", "ReferenceId": "8432869", "FullCitation": "Wang Z, et al. J. Clin. Invest. (1993) pmid: 8432869", "Include": "true"}, {"number": "184", "ReferenceId": "1898655", "FullCitation": "D Urso CM, et al. J. Clin. Invest. (1991) pmid: 1898655", "Include": "true"}, {"number": "185", "ReferenceId": "8537970", "FullCitation": "Restifo NP, et al. J. Natl. Cancer Inst. (1996) pmid: 8537970", "Include": "true"}, {"number": "186", "ReferenceId": "25294904", "FullCitation": "Sucker A, et al. Clin. Cancer Res. (2014) pmid: 25294904", "Include": "true"}, {"number": "187", "ReferenceId": "27261508", "FullCitation": "Zhao F, et al. Cancer Res. (2016) pmid: 27261508", "Include": "true"}, {"number": "188", "ReferenceId": "23784959", "FullCitation": "del Campo AB, et al. Int. J. Cancer (2014) pmid: 23784959", "Include": "true"}, {"number": "189", "ReferenceId": "27433843", "FullCitation": "Zaretsky JM, et al. N. Engl. J. Med. (2016) pmid: 27433843", "Include": "true"}, {"number": "190", "ReferenceId": "29025772", "FullCitation": "Gettinger S, et al. Cancer Discov (2017) pmid: 29025772", "Include": "true"}, {"number": "191", "ReferenceId": "28596308", "FullCitation": "Le DT, et al. Science (2017) pmid: 28596308", "Include": "true"}, {"number": "192", "ReferenceId": "29070816", "FullCitation": "Sade_Feldman M, et al. Nat Commun (2017) pmid: 29070816", "Include": "true"}, {"number": "193", "ReferenceId": "31217164", "FullCitation": "Gurjao C, et al. Cancer Immunol Res (2019) pmid: 31217164", "Include": "true"}, {"number": "194", "ReferenceId": "31008436", "FullCitation": "Middha S, et al. JCO Precis Oncol (2019) pmid: 31008436", "Include": "true"}, {"number": "195", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "196", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "197", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "198", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "199", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "200", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "201", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "202", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "203", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "204", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "205", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "206", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "207", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "208", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "209", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "210", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "211", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "212", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "213", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "214", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "215", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "216", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "217", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "218", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "219", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "220", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "221", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "222", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "223", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "224", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "225", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "226", "ReferenceId": "25873077", "FullCitation": "Jafri M, et al. Cancer Discov (2015) pmid: 25873077", "Include": "true"}, {"number": "227", "ReferenceId": "22619049", "FullCitation": "Guney S, et al. Genes Chromosomes Cancer (2012) pmid: 22619049", "Include": "true"}, {"number": "228", "ReferenceId": "18828156", "FullCitation": "Schwaenen C, et al. Genes Chromosomes Cancer (2009) pmid: 18828156", "Include": "true"}, {"number": "229", "ReferenceId": "20435884", "FullCitation": "Jardin F, et al. Blood (2010) pmid: 20435884", "Include": "true"}, {"number": "230", "ReferenceId": "18765795", "FullCitation": "Lenz G, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18765795", "Include": "true"}, {"number": "231", "ReferenceId": "9531609", "FullCitation": "Pinyol M, et al. Blood (1998) pmid: 9531609", "Include": "true"}, {"number": "232", "ReferenceId": "10086736", "FullCitation": "M\u00f8ller MB, et al. Leukemia (1999) pmid: 10086736", "Include": "true"}, {"number": "233", "ReferenceId": "12959350", "FullCitation": "Lossos IS, et al. Semin. Cancer Biol. (2003) pmid: 12959350", "Include": "true"}, {"number": "234", "ReferenceId": "9616165", "FullCitation": "Elenitoba_Johnson KS, et al. Blood (1998) pmid: 9616165", "Include": "true"}, {"number": "235", "ReferenceId": "17495976", "FullCitation": "Fitzgibbon J, et al. Leukemia (2007) pmid: 17495976", "Include": "true"}, {"number": "236", "ReferenceId": "10477703", "FullCitation": "Baur AS, et al. Blood (1999) pmid: 10477703", "Include": "true"}, {"number": "237", "ReferenceId": "21504712", "FullCitation": "Kreisel F, et al. Cancer Genet (2011) pmid: 21504712", "Include": "true"}, {"number": "238", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "239", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "240", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "241", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "242", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "243", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "244", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "245", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "246", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "247", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "248", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "249", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "250", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "251", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "252", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "253", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "254", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "255", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "256", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "257", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "258", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "259", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "260", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "261", "ReferenceId": "15134788", "FullCitation": "Weil R, et al. Curr. Opin. Immunol. (2004) pmid: 15134788", "Include": "true"}, {"number": "262", "ReferenceId": "23474202", "FullCitation": "Paul S, et al. Trends Immunol. (2013) pmid: 23474202", "Include": "true"}, {"number": "263", "ReferenceId": "27135977", "FullCitation": "Juilland M, et al. Curr. Opin. Hematol. (2016) pmid: 27135977", "Include": "true"}, {"number": "264", "ReferenceId": "26776161", "FullCitation": "Bognar MK, et al. Oncogene (2016) pmid: 26776161", "Include": "true"}, {"number": "265", "ReferenceId": "23149938", "FullCitation": "Chan W, et al. Mol. Cell. Biol. (2013) pmid: 23149938", "Include": "true"}, {"number": "266", "ReferenceId": "25352053", "FullCitation": "Brohl AS, et al. J. Clin. Immunol. (2015) pmid: 25352053", "Include": "true"}, {"number": "267", "ReferenceId": "23027925", "FullCitation": "Jeelall YS, et al. J. Exp. Med. (2012) pmid: 23027925", "Include": "true"}, {"number": "268", "ReferenceId": "18323416", "FullCitation": "Lenz G, et al. Science (2008) pmid: 18323416", "Include": "true"}, {"number": "269", "ReferenceId": "20799731", "FullCitation": "Lamason RL, et al. Biochemistry (2010) pmid: 20799731", "Include": "true"}, {"number": "270", "ReferenceId": "21266526", "FullCitation": "Dong G, et al. Clin. Cancer Res. (2011) pmid: 21266526", "Include": "true"}, {"number": "271", "ReferenceId": "19412164", "FullCitation": "Compagno M, et al. Nature (2009) pmid: 19412164", "Include": "true"}, {"number": "272", "ReferenceId": "26551667", "FullCitation": "da Silva Almeida AC, et al. Nat. Genet. (2015) pmid: 26551667", "Include": "true"}, {"number": "273", "ReferenceId": "27369867", "FullCitation": "Vallois D, et al. Blood (2016) pmid: 27369867", "Include": "true"}, {"number": "274", "ReferenceId": "27224912", "FullCitation": "Wu C, et al. Oncotarget (2016) pmid: 27224912", "Include": "true"}, {"number": "275", "ReferenceId": "26540570", "FullCitation": "Nagel D, et al. Oncotarget (2015) pmid: 26540570", "Include": "true"}, {"number": "276", "ReferenceId": "21324920", "FullCitation": "Naylor TL, et al. Cancer Res. (2011) pmid: 21324920", "Include": "true"}, {"number": "277", "ReferenceId": "23129749", "FullCitation": "Snow AL, et al. J. Exp. Med. (2012) pmid: 23129749", "Include": "true"}, {"number": "278", "ReferenceId": "22397314", "FullCitation": "Bu R, et al. Leuk. Lymphoma (2012) pmid: 22397314", "Include": "true"}, {"number": "279", "ReferenceId": "23699601", "FullCitation": "Morin RD, et al. Blood (2013) pmid: 23699601", "Include": "true"}, {"number": "280", "ReferenceId": "20544211", "FullCitation": "Montesinos_Rongen M, et al. Acta Neuropathol. (2010) pmid: 20544211", "Include": "true"}, {"number": "281", "ReferenceId": "22102703", "FullCitation": "Yan Q, et al. Haematologica (2012) pmid: 22102703", "Include": "true"}, {"number": "282", "ReferenceId": "26551670", "FullCitation": "Wang L, et al. Nat. Genet. (2015) pmid: 26551670", "Include": "true"}, {"number": "283", "ReferenceId": "16484591", "FullCitation": "Oshiro A, et al. Blood (2006) pmid: 16484591", "Include": "true"}, {"number": "284", "ReferenceId": "18633432", "FullCitation": "Fujiwara SI, et al. Leukemia (2008) pmid: 18633432", "Include": "true"}, {"number": "285", "ReferenceId": "25384343", "FullCitation": "Ma Y, et al. Eur. J. Med. Res. (2014) pmid: 25384343", "Include": "true"}, {"number": "286", "ReferenceId": "22842228", "FullCitation": "Krauthammer M, et al. Nat. Genet. (2012) pmid: 22842228", "Include": "true"}, {"number": "287", "ReferenceId": "22817889", "FullCitation": "Hodis E, et al. Cell (2012) pmid: 22817889", "Include": "true"}, {"number": "288", "ReferenceId": "25855536", "FullCitation": "Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536", "Include": "true"}, {"number": "289", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "290", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "291", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "292", "ReferenceId": "20685844", "FullCitation": "Thome M, et al. Cold Spring Harb Perspect Biol (2010) pmid: 20685844", "Include": "true"}, {"number": "293", "ReferenceId": "22435566", "FullCitation": "Lim KH, et al. Immunol. Rev. (2012) pmid: 22435566", "Include": "true"}, {"number": "294", "ReferenceId": "20525923", "FullCitation": "Milhollen MA, et al. Blood (2010) pmid: 20525923", "Include": "true"}, {"number": "295", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "296", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "297", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "298", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "299", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "300", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "301", "ReferenceId": "24167765", "FullCitation": "Maletzki C, et al. Oncoimmunology (2013) pmid: 24167765", "Include": "true"}, {"number": "302", "ReferenceId": "18177936", "FullCitation": "Miyashita K, et al. Leuk. Res. (2008) pmid: 18177936", "Include": "true"}, {"number": "303", "ReferenceId": "23960188", "FullCitation": "de Miranda NF, et al. J. Exp. Med. (2013) pmid: 23960188", "Include": "true"}, {"number": "304", "ReferenceId": "11021817", "FullCitation": "Starostik P, et al. Am. J. Pathol. (2000) pmid: 11021817", "Include": "true"}, {"number": "305", "ReferenceId": "11182043", "FullCitation": "Hiyama T, et al. Oncol. Rep. () pmid: 11182043", "Include": "true"}, {"number": "306", "ReferenceId": "12471623", "FullCitation": "Jordanova ES, et al. Int. J. Cancer (2003) pmid: 12471623", "Include": "true"}, {"number": "307", "ReferenceId": "19551857", "FullCitation": "Borie C, et al. Int. J. Cancer (2009) pmid: 19551857", "Include": "true"}, {"number": "308", "ReferenceId": "22916837", "FullCitation": "Degroote A, et al. Leuk. Lymphoma (2013) pmid: 22916837", "Include": "true"}, {"number": "309", "ReferenceId": "18181177", "FullCitation": "Pineda M, et al. Genes Chromosomes Cancer (2008) pmid: 18181177", "Include": "true"}, {"number": "310", "ReferenceId": "26008772", "FullCitation": "Cheah CY, et al. J. Clin. Pathol. (2015) pmid: 26008772", "Include": "true"}, {"number": "311", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "312", "ReferenceId": "23066952", "FullCitation": "Couronn\u00e9 L, et al. Leuk. Lymphoma (2013) pmid: 23066952", "Include": "true"}, {"number": "313", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "314", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "315", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "316", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_11_09 18:17:22", "OpName": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "842x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "22 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SOFT TISSUE", "disease_ontology": "Diffuse large B_cell lymphoma (NOS)", "flowcell_analysis": "2000018521", "gender": "male", "pathology_diagnosis": "diffuse large b cell lymphoma, c83.3 (do not cita) (int)", "percent_tumor_nuclei": "30", "pipeline_version": "v3.8.2", "purity_assessment": "68.2", "specimen": "ORD_1220222_01*US1179002.01", "study": "CLINICAL_HEME_COMPLETE", "test_request": "ORD_1220222_01", "test_type": "HemeComplete", "tissue_of_origin": "Testis", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": [{"bait_set": "R2", "mean_exon_depth": "267.9", "name": "SQ_US1179002.01_1", "nucleic_acid_type": "RNA"}, {"bait_set": "D2", "mean_exon_depth": "837.89", "name": "SQ_US1179002.01_2", "nucleic_acid_type": "DNA"}]}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.3397", "cds_effect": "645G>T", "depth": "730", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "33.97", "position": "chr7:2983885", "protein_effect": "K215N", "status": "known", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.4978", "cds_effect": "3926G>A", "depth": "671", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB3", "percent_reads": "49.78", "position": "chr12:56495736", "protein_effect": "R1309H", "status": "unknown", "strand": "+", "transcript": "NM_001982", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.1754", "cds_effect": "_30_59del89", "depth": "707", "equivocal": "false", "functional_effect": "nonsense", "gene": "B2M", "percent_reads": "17.54", "position": "chr15:45003714", "protein_effect": "M1?", "status": "likely", "strand": "+", "transcript": "NM_004048", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.1529", "cds_effect": "482_483insCGGGGTGCTCCACCGCGACATCAAGGACGAAAACATCCTTATCGACCTCAATCGCGGCGAGCTCAAGCTCATCGACTTCGGGTCGGGGGCGCTGCTCAAGGACACCGTCTACACGGACTTCGATGGTGAGCCAGGCCCGGGAGGGAGCTGCCCAGGTGACTCGGCCCGGCCCGGCCCAGTCCGGAGGCCTCGGCCAGTCTCCCGCGCCAGCCTTTTGTAAAGGTCATTGGGC", "depth": "811", "equivocal": "false", "functional_effect": "frameshift", "gene": "PIM1", "percent_reads": "15.29", "position": "chr6:37139142", "protein_effect": "T204fs*31", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.294", "cds_effect": "1100C>A", "depth": "687", "equivocal": "false", "functional_effect": "missense", "gene": "FANCC", "percent_reads": "29.4", "position": "chr9:97876965", "protein_effect": "T367K", "status": "unknown", "strand": "_", "transcript": "NM_000136", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.4145", "cds_effect": "59G>A", "depth": "608", "equivocal": "false", "functional_effect": "missense", "gene": "IDH1", "percent_reads": "41.45", "position": "chr2:209116217", "protein_effect": "R20Q", "status": "unknown", "strand": "_", "transcript": "NM_005896", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.4601", "cds_effect": "4123A>T", "depth": "852", "equivocal": "false", "functional_effect": "missense", "gene": "PRKDC", "percent_reads": "46.01", "position": "chr8:48801732", "protein_effect": "T1375S", "status": "unknown", "strand": "_", "transcript": "NM_006904", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.0156", "cds_effect": "598C>T", "depth": "1087", "equivocal": "false", "functional_effect": "missense", "gene": "VHL", "percent_reads": "1.56", "position": "chr3:10191605", "protein_effect": "R200W", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_000551", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3416", "cds_effect": "29C>T", "depth": "846", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "34.16", "position": "chr6:37138380", "protein_effect": "A10V", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.5205", "cds_effect": "3587G>A", "depth": "488", "equivocal": "false", "functional_effect": "missense", "gene": "GPR124", "percent_reads": "52.05", "position": "chr8:37699443", "protein_effect": "C1196Y", "status": "unknown", "strand": "+", "transcript": "NM_032777", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3165", "cds_effect": "379C>T", "depth": "910", "equivocal": "false", "functional_effect": "nonsense", "gene": "PIM1", "percent_reads": "31.65", "position": "chr6:37139039", "protein_effect": "Q127*", "status": "known", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.348", "cds_effect": "305G>A", "depth": "911", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "34.8", "position": "chr6:37138965", "protein_effect": "G102D", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.2802", "cds_effect": "529C>T", "depth": "1060", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "28.02", "position": "chr6:37139189", "protein_effect": "L177F", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.2995", "cds_effect": "4C>T", "depth": "878", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "29.95", "position": "chr6:37138355", "protein_effect": "L2F", "status": "known", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.5027", "cds_effect": "842A>G", "depth": "750", "equivocal": "false", "functional_effect": "missense", "gene": "MDM4", "percent_reads": "50.27", "position": "chr1:204515944", "protein_effect": "N281S", "status": "unknown", "strand": "+", "transcript": "NM_002393", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.1813", "cds_effect": "58_59insCTATCCAGCGTGAGTCTCTCCTACCCTCCCGCTCTGGTCCTTCCTCTCCCGCTCTGCA", "depth": "728", "equivocal": "false", "functional_effect": "frameshift", "gene": "B2M", "percent_reads": "18.13", "position": "chr15:45003802", "protein_effect": "T24fs*52", "status": "likely", "strand": "+", "transcript": "NM_004048", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.4928", "cds_effect": "550C>T", "depth": "970", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "49.28", "position": "chr6:37139210", "protein_effect": "L184F", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3784", "cds_effect": "935G>A", "depth": "732", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "37.84", "position": "chr6:37141860", "protein_effect": "S312N", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.2154", "cds_effect": "14880_15016>CTGAATC", "depth": "1509", "equivocal": "false", "functional_effect": "frameshift", "gene": "MLL2", "percent_reads": "21.54", "position": "chr12:49420733", "protein_effect": "P4961fs*1", "status": "likely", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3445", "cds_effect": "526T>G", "depth": "1161", "equivocal": "false", "functional_effect": "missense", "gene": "BIRC3", "percent_reads": "34.45", "position": "chr11:102195766", "protein_effect": "F176V", "status": "unknown", "strand": "+", "transcript": "NM_001165", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3634", "cds_effect": "524G>A", "depth": "688", "equivocal": "false", "functional_effect": "missense", "gene": "FANCE", "percent_reads": "36.34", "position": "chr6:35423799", "protein_effect": "G175D", "status": "unknown", "strand": "+", "transcript": "NM_021922", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.444", "cds_effect": "3938A>T", "depth": "491", "equivocal": "false", "functional_effect": "missense", "gene": "GPR124", "percent_reads": "44.4", "position": "chr8:37699794", "protein_effect": "D1313V", "status": "unknown", "strand": "+", "transcript": "NM_032777", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.339", "cds_effect": "794T>C", "depth": "711", "equivocal": "false", "functional_effect": "missense", "gene": "MYD88", "percent_reads": "33.9", "position": "chr3:38182641", "protein_effect": "L265P", "status": "known", "strand": "+", "transcript": "NM_002468", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.8393", "cds_effect": "2396G>T", "depth": "778", "equivocal": "false", "functional_effect": "missense", "gene": "KDM4C", "percent_reads": "83.93", "position": "chr9:7049172", "protein_effect": "G799V", "status": "unknown", "strand": "+", "transcript": "NM_015061", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3401", "cds_effect": "199C>T", "depth": "197", "equivocal": "false", "functional_effect": "missense", "gene": "DUSP2", "percent_reads": "34.01", "position": "chr2:96810895", "protein_effect": "L67F", "status": "unknown", "strand": "_", "transcript": "NM_004418", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.2031", "cds_effect": "290G>A", "depth": "64", "equivocal": "false", "functional_effect": "missense", "gene": "RAD51", "percent_reads": "20.31", "position": "chr15:40994068", "protein_effect": "R97H", "status": "unknown", "strand": "+", "transcript": "NM_133487", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3471", "cds_effect": "947G>C", "depth": "801", "equivocal": "false", "functional_effect": "missense", "gene": "TBL1XR1", "percent_reads": "34.71", "position": "chr3:176756201", "protein_effect": "W316S", "status": "unknown", "strand": "_", "transcript": "NM_024665", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3351", "cds_effect": "83G>A", "depth": "734", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "33.51", "position": "chr6:37138549", "protein_effect": "G28D", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.2896", "cds_effect": "182G>A", "depth": "511", "equivocal": "false", "functional_effect": "missense", "gene": "FGF19", "percent_reads": "28.96", "position": "chr11:69518463", "protein_effect": "R61H", "status": "unknown", "strand": "_", "transcript": "NM_005117", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3491", "cds_effect": "410G>T", "depth": "888", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "34.91", "position": "chr6:37139070", "protein_effect": "G137V", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3489", "cds_effect": "241C>T", "depth": "837", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "34.89", "position": "chr6:37138901", "protein_effect": "P81S", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3533", "cds_effect": "169C>G", "depth": "702", "equivocal": "false", "functional_effect": "missense", "gene": "PIM1", "percent_reads": "35.33", "position": "chr6:37138635", "protein_effect": "R57G", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.4859", "cds_effect": "1037C>T", "depth": "710", "equivocal": "false", "functional_effect": "missense", "gene": "IKBKE", "percent_reads": "48.59", "position": "chr1:206652330", "protein_effect": "A346V", "status": "unknown", "strand": "+", "transcript": "NM_014002", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3495", "cds_effect": "29C>T", "depth": "515", "equivocal": "false", "functional_effect": "missense", "gene": "ETS1", "percent_reads": "34.95", "position": "chr11:128391861", "protein_effect": "T10I", "status": "unknown", "strand": "_", "transcript": "NM_005238", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3342", "cds_effect": "208G>T", "depth": "742", "equivocal": "false", "functional_effect": "nonsense", "gene": "PIM1", "percent_reads": "33.42", "position": "chr6:37138775", "protein_effect": "E70*", "status": "unknown", "strand": "+", "transcript": "NM_002648", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"allele_fraction": "0.3226", "cds_effect": "1757C>T", "depth": "527", "equivocal": "false", "functional_effect": "missense", "gene": "BCL11B", "percent_reads": "32.26", "position": "chr14:99641416", "protein_effect": "A586V", "status": "unknown", "strand": "_", "transcript": "NM_138576", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "0", "equivocal": "false", "gene": "CDKN2B", "number_of_exons": "5 of 5", "position": "chr9:21998748_22101832", "ratio": "0.32", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "5 of 5", "position": "chr9:21954944_21998002", "ratio": "0.33", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1179002.01_2"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "21.99", "status": "high", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}